​

Windtree Therapeutics (WINT) Stock Forecast, Price Target & Predictions

OverviewRevenueFinancialsChart

WINT Stock Rating

Windtree Therapeutics stock's rating consensus is Buy, based on 5 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 3 Buy (60.00%), 2 Hold (40.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 5 0 2 3 Strong Sell Sell Hold Buy Strong Buy

WINT Price Target Upside V Benchmarks

TypeNameUpside
StockWindtree Therapeutics-
SectorHealthcare Stocks 24.81%
IndustryBiotech Stocks 65.78%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$0.60$0.60$0.60
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 25--1--1
May, 25--1--1
Apr, 25--1--1
Mar, 25--1--1
Feb, 25--1--1
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jun 06, 2021OppenheimerOutperforminitialise

Financial Forecast

EPS Forecast

$-2K $-1K $-900 $-600 $-300 $0 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-980.20$-92.23$-104.35----
Avg Forecast$-1.16K$-94.86$-5.66$-2.86$-10.98$-11.34$-0.71
High Forecast$-1.16K$-74.31$-5.66$-2.86$-10.98$-11.34$-0.71
Low Forecast$-1.16K$-115.19$-5.66$-2.86$-10.98$-11.34$-0.71
Surprise %-15.57%-2.77%1743.64%----

Revenue Forecast

Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported-------
Avg Forecast$150.00K-$2.00M$12.20M$12.40M--
High Forecast$150.00K-$2.00M$12.20M$12.40M--
Low Forecast$150.00K-$2.00M$12.20M$12.40M--
Surprise %-------

Net Income Forecast

$-300M $-240M $-180M $-120M $-60M $0 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-39.21M$-20.29M$-5.49M----
Avg Forecast$-255.42M$-20.85M$-1.25M$-629.20K$-2.42M$-2.49M$-156.20K
High Forecast$-255.42M$-16.35M$-1.25M$-629.20K$-2.42M$-2.49M$-156.20K
Low Forecast$-255.42M$-25.34M$-1.25M$-629.20K$-2.42M$-2.49M$-156.20K
Surprise %-84.65%-2.66%340.65%----

WINT Forecast FAQ

Is Windtree Therapeutics stock a buy?

Windtree Therapeutics stock has a consensus rating of Buy, based on 5 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 3 Buy, 2 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Windtree Therapeutics is a favorable investment for most analysts.

What is Windtree Therapeutics's price target?

Windtree Therapeutics's price target, set by 5 Wall Street analysts, averages - over the next 12 months. The price target range spans from - at the low end to - at the high end, suggesting a potential 0% change from the previous closing price of $0.6.

How does Windtree Therapeutics stock forecast compare to its benchmarks?

Windtree Therapeutics's stock forecast shows a 0% downside, underperforming the average forecast for the healthcare stocks sector (24.81%) and underperforming the biotech stocks industry (65.78%).

What is the breakdown of analyst ratings for Windtree Therapeutics over the past three months?

  • June 2025: 0% Strong Buy, 0% Buy, 100.00% Hold, 0% Sell, 0% Strong Sell.
  • May 2025: 0% Strong Buy, 0% Buy, 100.00% Hold, 0% Sell, 0% Strong Sell.
  • April 2025: 0% Strong Buy, 0% Buy, 100.00% Hold, 0% Sell, 0% Strong Sell.

What is Windtree Therapeutics’s EPS forecast?

Windtree Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-2.86, marking a -97.26% decrease from the reported $-104 in 2024. Estimates for the following years are $-10.98 in 2026, $-11.34 in 2027, and $-0.71 in 2028.

What is Windtree Therapeutics’s revenue forecast?

Windtree Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $12.2M, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $12.4M, followed by $0 for 2027, and $0 for 2028.

What is Windtree Therapeutics’s net income forecast?

Windtree Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-629K, representing a -88.53% decrease from the reported $-5.487M in 2024. Projections indicate $-2.416M in 2026, $-2.495M in 2027, and $-156K in 2028.